Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Mesoblast (Nasdaq: MESO) Announces Exemption from U.S. Tariffs for Allogeneic Cellular Products

Mesoblast (Nasdaq: MESO) has confirmed that its allogeneic cellular products, including Ryoncil® and Revascor®, will be exempt from U.S. tariffs. This exemption is made possible because the company’s products are designated as “U.S. Country of Origin” products. All products are manufactured using U.S. donors …

Team Kalkine | 04 April 2025

Telix Pharmaceuticals (ASX/NASDAQ: TLX) Appoints Anne Whitaker as Non-Executive Director

Telix Pharmaceuticals (ASX/NASDAQ: TLX) has appointed Anne Whitaker as a Non-Executive Director, effective April 7, 2025. Whitaker's appointment brings a wealth of knowledge and experience to the company, stemming from over three decades in the pharmaceutical, biotech, and specialty pharmaceutical sectors.

Team Kalkine | 04 April 2025

Markets in Turmoil: Trade War Escalation Sparks Sharp Sell-Off Across Assets

U.S. stock futures extended sharp losses Friday, with the S&P 500 and Dow down about 2.5% and Nasdaq 100 off 2.8%, deepening the recent sell-off that pushed the S&P into correction territory. The decline follows China’s retaliatory 34% tariff on U.S. imports, escalating the …

Team Kalkine | 04 April 2025

Market Turmoil as Trump’s Tariffs Trigger Global Sell-Off

Dow and S&P 500 futures fell over 2% and 3%, respectively, while Nasdaq 100 futures plunged more than 4%. Companies with global supply chains suffered sharp declines, with Apple down 7.5%, Nike 7%, and Tesla 7.2%. Mega-cap tech stocks and retailers also saw significant …

Team Kalkine | 03 April 2025

FDA Grants Accelerated Approval for Novartis' Vanrafia® in IgA Nephropathy

Novartis has announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia® (atrasentan), a potent and selective endothelin A (ETA) receptor antagonist, for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at high …

Team Kalkine | 03 April 2025

PVH Exceeds Q4 Earnings Estimates Despite Revenue Decline, Plans $500M Share Buyback

PVH Corp. (NYSE:PVH), the parent company of Calvin Klein and Tommy Hilfiger, posted better-than-expected Q4 earnings, despite a 5% year-over-year revenue decline. The company also unveiled plans for a $500 million share repurchase program.

Team Kalkine | 03 April 2025

Johnson & Johnson Stock Plunges as Judge Rejects $10B Talc Settlement Plan

Johnson & Johnson (NYSE:JNJ) suffered a significant legal blow on Tuesday, as a Texas bankruptcy judge rejected its $10 billion proposal to resolve thousands of lawsuits alleging its talc-based baby powder caused cancer. The ruling sent J&J’s stock tumbling 7.6%, closing at $153.25.

Team Kalkine | 03 April 2025

Tesla's Q1 Deliveries Drop 13% Amid Consumer Backlash and Political Controversy

Tesla (NASDAQ:TSLA) reported a 13% decline in global vehicle deliveries in the first quarter of 2025, signaling growing challenges for the EV giant. The company delivered 336,681 vehicles, significantly missing analysts’ expectations of 396,960. The drop comes amid increased competition, consumer backlash, and CEO …

Team Kalkine | 03 April 2025

Nintendo Bets Big on Switch 2 With Higher Price and New Features

High Demand Expected:The originalSwitch sold nearly 151 million units, making it Nintendo’sbest-selling home consoleever.

Team Kalkine | 03 April 2025

Market Update: Stocks, Commodities, and Economic Trends Amid Tariff Uncertainty

US stock futures declined on Wednesday, with S&P 500 and Nasdaq 100 down 0.4% and Dow Jones futures falling nearly 80 points, as investors awaited President Trump’s tariff announcement. Reports suggested a possible 20% tariff on most imports, though details remain uncertain. The White …

Team Kalkine | 02 April 2025
Support

Hi! How can we help you today?

Loading…